Licensing deal financials databases

One of the prerequisites of biopharmaceutical licensing negotiations is understanding the possible licensing deal structures available and the financial impact of different deal arrangements. Furthermore, understanding the financial impact of upfront, milestone payments, sublicense fees and royalties on licensing deals can also be useful benchmark tools in the licensing negotiation process, presentations to potential investors and business plan preparations.

PharmaPlusPharmaPlus has created two complementary licensing deal financials databases.

PharmaPlus Deal Financials – Research institutes

The PharmaPlus Deal Financials – Research Institutes database focuses on biopharmaceutical licensing deal financials between non-profit research organizations and biopharmaceutical companies.

Our database solely displays licensing deals for which at least one financial component (potential deal size, upfront, milestones, royalties, sublicensing fees, guaranteed annual minimums, equity) is available.

PharmaPlus Deal Financials – Company2

The PharmaPlus Deal Financials – Company2 database was created in 1996 and until today solely focuses on licensing deal financials for not yet registered therapeutics between biopharmaceutical companies.

Our database solely displays licensing deals for which at least one financial component (potential deal size, upfront, milestones, research funding, profit sharing, royalties, equity) is available. Next to these financial components our database offers information as far as available on compound class, compound name, disease area and/or indications covered, development stage at deal closure and licensed territory.

Next to its use as a stand-alone, the PharmaPlus Deal Financials – Company2 can be considered as a complementary database to the PharmaPlus Deal Financials – Research institutes database, because it contains sublicensing deals between biopharmaceutical companies for therapeutics originating from research institutes. Combined information from these two databases can be a valuable intelligence tool for start-ups and SMEs to support their business plan preparations and their presentations to potential investors.

Customized list of benchmark deals

We can provide you with a list of benchmark deals from our PharmaPlus Deal Financials databases, tailored specifically to your needs, with a minimum of 5 and a maximum of 25 licensing deals at USD 20 per deal / € 18 per deal.

Please contact us for further information.